METHODOLOGY The Research and Education Newsletter of Houston Methodist
Houston Methodist RNACore Awarded $4.8 Million for RNA Therapeutics and Research by the Cancer Prevention and Research Institute of Texas by Maitreyi Muralidhar
Scientists from the Houston Methodist Research Institute RNACore will receive $ 4.8 million from the Cancer Prevention and Research Institute of Texas (CPRIT) for pursuing RNA-based therapeutics and research. According to CPRIT, the award, called the Core Facilities Support Award (CFSA), “supports the establishment or enhancement of core research facilities that will provide valuable services to enhance the outcomes of scientifically meritorious cancer research projects”.
John Cooke, M.D., Ph.D., the principal investigator of the CPRIT grant, believes that this award will be a great boost to the research being conducted at the RNACore which serves as the RNAcore for the Progenitor Cell Biology Consortium of the National Heart, Lung and Blood Institute. >> CONT. PAGE THREE
The RNA Core will be the first entity in Texas to generate the new class of drugs known as RNA Therapeutics. These drugs can modify the function of cells in a beneficial manner. The grant funding will support the development and generation of RNA therapeutics, particularly for cancer immunotherapy. – John Cooke, M.D., Ph.D. Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research
Published on Jun 23, 2015